Self Assembling Peptide P11-4 in Patients With Early Occlusal Carious Lesions
Primary Purpose
Dental Caries
Status
Completed
Phase
Phase 1
Locations
Study Type
Interventional
Intervention
self assembling peptide P11-4 (Curodont™ Repair)
fluoride varnish (Duraphat®)
Sponsored by
About this trial
This is an interventional treatment trial for Dental Caries
Eligibility Criteria
Inclusion Criteria:
- Early occlusal carious lesions (without cavity) on permanent molar "6" or "7" at eruption which does not require an invasive treatment
- Age ≥ 5 years
- Size and form of the lesions: the lesions must both be fully visible and assessable and accessible
- Willing and able to attend the on-study visits and to observe good oral hygiene throughout the study
- Written informed consent before participation in the study
Exclusion Criteria:
- Evidence of tooth erosion
- Fluoride varnish application < 3 months prior to study treatment
- History of head and neck illnesses (e.g. head/neck cancer)
- Any pathology or concomitant medication affecting salivary flow or dry mouth
- Any metabolic disorders affecting bone turnover
- Concurrent participation in another clinical trial
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Active Comparator
Arm Label
intervention
control
Arm Description
intervention group, self assembling peptide P11-4 (Curodont™ Repair) and fluoride varnish (Duraphat®)
control group, only Fluoride varnish (Duraphat®)
Outcomes
Primary Outcome Measures
Caries Activity and Progression Assessment Using LASER Fluorescence Readings by Diagnodent® Device.
Evaluation of the additional therapeutic benefit of Curodont™ compared to fluoride varnish (Duraphat®) alone on early occlusal carious lesions using LASER "Light Amplification by Stimulated Emission of Radiation" fluorescence readings by Diagnodent® device.
Diagnodent® device measures the caries activity using LASER fluorescence of bacterial secretions in the caries lesion. The readings range from 0 to 99; 0 means no bacterial activity in the carious lesion whereas 99 refers to high bacterial and caries activity.
Effect via the changes in LASER fluorescence readings between Baseline and 6-months recall (Change = Baseline value - 6 months value). Higher positive change value means caries regression, whereas lower positive or negative change value refers to caries progression.
Secondary Outcome Measures
Visual Analog Scale of Lesion Progression (VAS)
Visual Analog Scale of lesion progression (VAS), Effect via t test between Baseline and 6-months recall VAS values range from -100 % to +100 %. The value of -100 means that the carious lesion is strongly remineralising, the value of 0 means that the lesion is arrested, and the value of +100 means that the lesion is strongly progressing.
ICDAS Classification Index
Number of patients who have improvement on the ICDAS classification index (International Caries Detection and Assessment System), changes from Baseline to 6-months recall.
This carries clinical index range from 0 to 6. The values mean:
0 No evidence of caries
Initial caries
Distinct visual change in enamel
Localised enamel breakdown due to caries with no visible dentine
Underlying dark shadow from dentine
Distinct cavity with visible dentine
Extensive distinct cavity with visible dentine. During the study, a change from level to lower level number (e.g. from 2 to 1) in patients means that the carious lesion is regressed.
Caries Activity Assessment According to Nyvad Criteria
Caries activity assessment according to Nyvad criteria, number of participants still have active lesions overall study.
This assessment includes two clinical judgment inserts: active lesion or inactive lesion basing on visual-tactile surface characteristics of the caries lesions such as integrity, texture, translucency/opacity, lesion location, and surface color.
During the study, an alteration from active lesion to in active lesion means an improvement.
Full Information
NCT ID
NCT02724592
First Posted
March 7, 2016
Last Updated
March 15, 2021
Sponsor
University Medicine Greifswald
1. Study Identification
Unique Protocol Identification Number
NCT02724592
Brief Title
Self Assembling Peptide P11-4 in Patients With Early Occlusal Carious Lesions
Official Title
Effect of Self Assembling Peptide P11-4 in Patients With Early Occlusal Carious Lesions: A Mono-centre, Controlled, Single-blinded, Randomised Study
Study Type
Interventional
2. Study Status
Record Verification Date
March 2021
Overall Recruitment Status
Completed
Study Start Date
February 2013 (undefined)
Primary Completion Date
April 2014 (Actual)
Study Completion Date
October 2014 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University Medicine Greifswald
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
Objectives: Occlusal surfaces of erupting permanent molars are highly prone to caries. Self-assembling peptide (P11-4) has proven to enhance biomimetic mineralization of early carious lesions. Aim of this study was to evaluate safety, clinical applicability and effect of using P11-4 (Curodont™ Repair) in non-invasive treatment of early occlusal lesions.
Methods: 70 patients with active early occlusal lesions (ICDAS-II:1-3) on first or second permanent molars at eruption will be allocated in this randomized, controlled, single blinded study to test (Curodont™ Repair+Duraphat®) or control (Duraphat®) groups.
Detailed Description
Objectives: Occlusal surfaces of erupting permanent molars are high prone to caries. Self-assembling peptide (P11-4) has proven to enhance biomimetic mineralization of early carious lesions. Aim of this study was to evaluate safety, clinical applicability and effect of using P11-4 (Curodont™ Repair) in non-invasive treatment of early occlusal lesions.
Methods: 70 patients with active early occlusal lesions (ICDAS-II:1-3) on first or second permanent molars at eruption will be allocated in this randomized, controlled, single blinded study to test (Curodont™ Repair+Duraphat®) or control (Duraphat®) groups. Safety and applicability will be evaluated using dentist's/patient's questionnaires about adverse events, difficulties of application and satisfaction with procedure. Lesions will be assessed at baseline and recalls after 3 and 6 months regarding caries activity, clinical status (ICDAS-II) and with Diagnodent®. The Visual Analog Scale (VAS) of regression and of lesion size in addition to the Global Impression of Change Questionnaire will also be assessed. At every recall, fluoride varnish will be applied on lesions and patients received oral health instructions.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Dental Caries
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 1, Phase 2
Interventional Study Model
Parallel Assignment
Masking
Participant
Allocation
Randomized
Enrollment
70 (Actual)
8. Arms, Groups, and Interventions
Arm Title
intervention
Arm Type
Experimental
Arm Description
intervention group, self assembling peptide P11-4 (Curodont™ Repair) and fluoride varnish (Duraphat®)
Arm Title
control
Arm Type
Active Comparator
Arm Description
control group, only Fluoride varnish (Duraphat®)
Intervention Type
Device
Intervention Name(s)
self assembling peptide P11-4 (Curodont™ Repair)
Intervention Description
Applying of self assembling peptide P11-4 (Curodont™ Repair) on teeth with initial caries lesions
Intervention Type
Device
Intervention Name(s)
fluoride varnish (Duraphat®)
Intervention Description
Applying fluoride varnish (Duraphat®) on teeth with initial caries lesions
Primary Outcome Measure Information:
Title
Caries Activity and Progression Assessment Using LASER Fluorescence Readings by Diagnodent® Device.
Description
Evaluation of the additional therapeutic benefit of Curodont™ compared to fluoride varnish (Duraphat®) alone on early occlusal carious lesions using LASER "Light Amplification by Stimulated Emission of Radiation" fluorescence readings by Diagnodent® device.
Diagnodent® device measures the caries activity using LASER fluorescence of bacterial secretions in the caries lesion. The readings range from 0 to 99; 0 means no bacterial activity in the carious lesion whereas 99 refers to high bacterial and caries activity.
Effect via the changes in LASER fluorescence readings between Baseline and 6-months recall (Change = Baseline value - 6 months value). Higher positive change value means caries regression, whereas lower positive or negative change value refers to caries progression.
Time Frame
6 months
Secondary Outcome Measure Information:
Title
Visual Analog Scale of Lesion Progression (VAS)
Description
Visual Analog Scale of lesion progression (VAS), Effect via t test between Baseline and 6-months recall VAS values range from -100 % to +100 %. The value of -100 means that the carious lesion is strongly remineralising, the value of 0 means that the lesion is arrested, and the value of +100 means that the lesion is strongly progressing.
Time Frame
6 months
Title
ICDAS Classification Index
Description
Number of patients who have improvement on the ICDAS classification index (International Caries Detection and Assessment System), changes from Baseline to 6-months recall.
This carries clinical index range from 0 to 6. The values mean:
0 No evidence of caries
Initial caries
Distinct visual change in enamel
Localised enamel breakdown due to caries with no visible dentine
Underlying dark shadow from dentine
Distinct cavity with visible dentine
Extensive distinct cavity with visible dentine. During the study, a change from level to lower level number (e.g. from 2 to 1) in patients means that the carious lesion is regressed.
Time Frame
6 months
Title
Caries Activity Assessment According to Nyvad Criteria
Description
Caries activity assessment according to Nyvad criteria, number of participants still have active lesions overall study.
This assessment includes two clinical judgment inserts: active lesion or inactive lesion basing on visual-tactile surface characteristics of the caries lesions such as integrity, texture, translucency/opacity, lesion location, and surface color.
During the study, an alteration from active lesion to in active lesion means an improvement.
Time Frame
6 months
10. Eligibility
Sex
All
Minimum Age & Unit of Time
5 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
Early occlusal carious lesions (without cavity) on permanent molar "6" or "7" at eruption which does not require an invasive treatment
Age ≥ 5 years
Size and form of the lesions: the lesions must both be fully visible and assessable and accessible
Willing and able to attend the on-study visits and to observe good oral hygiene throughout the study
Written informed consent before participation in the study
Exclusion Criteria:
Evidence of tooth erosion
Fluoride varnish application < 3 months prior to study treatment
History of head and neck illnesses (e.g. head/neck cancer)
Any pathology or concomitant medication affecting salivary flow or dry mouth
Any metabolic disorders affecting bone turnover
Concurrent participation in another clinical trial
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Mohammad Alkilzy, Dr. PhD
Organizational Affiliation
University of Greifswald
Official's Role
Principal Investigator
12. IPD Sharing Statement
Plan to Share IPD
No
Citations:
PubMed Identifier
28892645
Citation
Alkilzy M, Tarabaih A, Santamaria RM, Splieth CH. Self-assembling Peptide P11-4 and Fluoride for Regenerating Enamel. J Dent Res. 2018 Feb;97(2):148-154. doi: 10.1177/0022034517730531. Epub 2017 Sep 11.
Results Reference
derived
Learn more about this trial
Self Assembling Peptide P11-4 in Patients With Early Occlusal Carious Lesions
We'll reach out to this number within 24 hrs